A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THREE DIFFERENT POTENCY LEVELS OF V181 (DENGUE QUADRIVALENT VACCINE RDENV¿30 [LIVE, ATTENUATED]) IN HEALTHY ADULTS
- Registry ID
- V181-003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2022-09-23
- Last update
- 2022-03-11
Conditions
View on source registry